Barclays Maintains Overweight Rating for Exscientia: Here's What You Need To Know

Barclays has decided to maintain its Overweight rating of Exscientia EXAI and lower its price target from $40.00 to $12.00.

Shares of Exscientia are trading down 1.81% over the last 24 hours, at $7.05 per share.

A move to $12.00 would account for a 70.21% increase from the current share price.

About Exscientia

Exscientia PLC is an artificial intelligence-driven pharma tech company committed to discovering, designing, and developing drugs. Its patient-first AI process is comprised of Precision Target, Precision Design, Precision Experiment, and Precision Medicine. Its revenue is generated from Service fees related to drug discovery collaboration agreements it is utilizing its proprietary technology to develop novel Intellectual Property (IP); and Licensing fees related to drug discovery agreements.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.